Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Russian Federation Government has granted $5m funding to Incuron to provide support for the research and clinical development of Curaxins under Skolkovo initiative.
Subscribe to our email newsletter
Curaxins are synthetic small molecules intended to simultaneously target major cell stress response pathways that are frequently deregulated in cancer.
Incuron CEO Andrei Leonov said this prestigious Skolkovo grant significantly raises the profile of their work with Curaxins in oncology.
"Moreover, it may enable us to explore additional potential applications of this novel class of therapeutic agents," Leonov said.